This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cell Therapeutics' CEO Hosts Annual Shareholder Meeting (Transcript)

We believe this amendment is important in order for us to continue to access capital markets from time to time to fund our business operations as we move our products forward. Do I hear a motion to approve this amendment?

Unidentified Company Representative


Dan Eramian

Do I hear a second?

Unidentified Company Speaker


Dan Eramian

A motion to approve this matter has been made and seconded. If there is no discussion we will speak to vote. The third matter to be considered is a proposal to approve an amendment to our 2007 Equity Incentive Plan to increase the number of shares available for issuance under the plan by an additional 15 million shares of common stock. The proposed amendments will facilitate our ability to continue to award meaningful incentives to our executive officers and key employees pursuant to the 2007 Equity Incentive Plan to attract and retain outstanding and highly skilled individuals in a very competitive labor market.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs